Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma

...table treatments for cancer patients. In addition to the Phase 3 HCC trial, lso is also treating patients in a Phase 3 trial for metastatic colorectal canc...hat nonetheless have implications for patient morbidity and even mortality. lso has completed a Phase 1/2 trial and has initiated a Phase 2a trial in benig...

Light Sciences Oncology Raises $40.1 Million in Series C Financing

....1 million in a Series C round of financing. The company raised $97 million in its first two rounds of financing. Investor names were not disclosed. lso plans to use the funds in the continued development of Light Infusion Therapy (Litx), which includes two ongoing Phase III clinical trials in patients...

Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate

...ia (BPH), or enlargement of the prostate, using Light Infusion Therapy(TM) (Litx(TM)), an innovative light-activated drug treatment under development. lso plans to conduct a 12-patient, Phase I/II dose-escalation study at four sites in the United States as well as a 40-patient, Phase IIa study in Austral...

LSO in Biological Technology

Light Sciences Oncology Appoints David P. Holveck to Its Board of Directors

...late-stage development of our light-activated drug therapy." "Joining the lso board is a great opportunity to help guide this dynamic company in its futu...ver, the Company has completed a Phase II clinical trial of Litx in glioma. lso has widened the scope of potential therapeutic applications for Litx to inc...